4.3 Article

The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men

Journal

JOURNAL OF SEXUAL MEDICINE
Volume 12, Issue 8, Pages 1660-1686

Publisher

ELSEVIER SCI LTD
DOI: 10.1111/jsm.12952

Keywords

Testosterone Deficiency; Hypogonadism; Etiology of Hypogonadism; Assessment of Hypogonadism; Treatment of Hypogonadism

Funding

  1. Allergan
  2. Evidera
  3. Ixchelsis
  4. Palatin
  5. Menarini
  6. NIH
  7. Urology Care Foundation
  8. AUA
  9. AMS
  10. Coloplast
  11. Bayer-Schering
  12. Besins
  13. Lilly
  14. Pfizer Inc.
  15. Auxilium
  16. Endo Pharmaceuticals
  17. Theralogix
  18. Ibsa
  19. Bayer
  20. Intercept
  21. Ely Lilly
  22. Prostrakan
  23. Antares
  24. Warner Chilcott
  25. Repros
  26. Capital Region Medical Foundation
  27. Janssen Cilag
  28. Johnson and Johnson
  29. Endo
  30. Eli Lilly

Ask authors/readers for more resources

IntroductionIn 2014, the International Society for Sexual Medicine (ISSM) convened a panel of experts to develop an evidence-based process of care for the diagnosis and management of testosterone deficiency (TD) in adult men. The panel considered the definition, epidemiology, etiology, physiologic effects, diagnosis, assessment and treatment of TD. It also considered the treatment of TD in special populations and commented on contemporary controversies about testosterone replacement therapy, cardiovascular risk and prostate cancer. AimThe aim was to develop clearly worded, practical, evidenced-based recommendations for the diagnosis and treatment of diagnosis and management of TD for clinicians without expertise in endocrinology, such as physicians in family medicine and general urology practice. MethodA comprehensive literature review was performed, followed by a structured, 3-day panel meeting and 6-month panel consultation process using electronic communication. The final guideline was compiled from reports by individual panel members on areas reflecting their special expertise, and then agreed by all through an iterative process. ResultsThis article contains the report of the ISSM TD Process of Care Committee. It offers a definition of TD and recommendations for assessment and treatment in different populations. Finally, best practice treatment recommendations are presented to guide clinicians, both familiar and unfamiliar with TD. ConclusionDevelopment of a process of care is an evolutionary process that continually reviews data and incorporates the best new research. We expect that ongoing research will lead to new insights into the pathophysiology of TD, as well as new, efficacious and safe treatments. We recommend that this process of care be reevaluated and updated by the ISSM in 4 years. Dean JD, McMahon CG, Guay AT, Morgentaler A, Althof SE, Becher EF, Bivalacqua TJ, Burnett AL, Buvat J, El Meliegy A, Hellstrom WJG, Jannini EA, Maggi M, McCullough A, Torres LO, and Zitzmann M. The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med 2015;12:1660-1686.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available